B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine

Paola Rossi, Raffaele Difrancia, Vincenzo Quagliariello, Elena Savino, Paolo Tralongo, Cinzia Lucia Randazzo, Massimiliano Berretta

Research output: Contribution to journalReview article

Abstract

Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.

Original languageEnglish
Pages (from-to)24837-24856
Number of pages20
JournalOncotarget
Volume9
Issue number37
DOIs
Publication statusPublished - May 15 2018

Fingerprint

Grifola
Integrative Medicine
Reishi
Glucans
Agaricales
Complementary Therapies
Breast Neoplasms
Dietary Supplements
Phytotherapy
Neoplasms
Gastrointestinal Neoplasms
Translational Medical Research
Insurance Benefits
Epidemiologic Studies
Randomized Controlled Trials
Animal Models
Inflammation
Food
Survival
Research

Cite this

B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer : an example of complementary and integrative medicine. / Rossi, Paola; Difrancia, Raffaele; Quagliariello, Vincenzo; Savino, Elena; Tralongo, Paolo; Randazzo, Cinzia Lucia; Berretta, Massimiliano.

In: Oncotarget, Vol. 9, No. 37, 15.05.2018, p. 24837-24856.

Research output: Contribution to journalReview article

Rossi, Paola ; Difrancia, Raffaele ; Quagliariello, Vincenzo ; Savino, Elena ; Tralongo, Paolo ; Randazzo, Cinzia Lucia ; Berretta, Massimiliano. / B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer : an example of complementary and integrative medicine. In: Oncotarget. 2018 ; Vol. 9, No. 37. pp. 24837-24856.
@article{0bb7abf278c9403386ae306640d2aa91,
title = "B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine",
abstract = "Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.",
author = "Paola Rossi and Raffaele Difrancia and Vincenzo Quagliariello and Elena Savino and Paolo Tralongo and Randazzo, {Cinzia Lucia} and Massimiliano Berretta",
year = "2018",
month = "5",
day = "15",
doi = "10.18632/oncotarget.24984",
language = "English",
volume = "9",
pages = "24837--24856",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "37",

}

TY - JOUR

T1 - B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer

T2 - an example of complementary and integrative medicine

AU - Rossi, Paola

AU - Difrancia, Raffaele

AU - Quagliariello, Vincenzo

AU - Savino, Elena

AU - Tralongo, Paolo

AU - Randazzo, Cinzia Lucia

AU - Berretta, Massimiliano

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.

AB - Culinary and medicinal mushrooms are widely used in Asian countries, both as dietary supplements and as nutraceutical foods. They have recently become popular in Europe, as well, for their nutritional and health benefits. In particular, epidemiological studies conducted in Asia suggest that mushroom intake, together with other phytotherapy substances, protects against cancer, specifically gastrointestinal (GI) and breast cancers. Most of the data come from in vitro studies and in vivo experimental animal models. Therefore, in order to translate the updated knowledge to clinical research (i.e., from bench to bedside) a systematic translational research program should be initiated. Future randomized controlled trials comparing the effects of G. frondosa and G. lucidum on conventional treatment outcomes are warranted. The purpose of this review was to describe the emerging mechanisms of action of the mushrooms' anticancer functions which makes their use in clinical practice so promising. Clinical effects of mycotherapy (specifically, the use of Ganoderma lucidum and Grifola frondosa) on long-term survival, tumor response, host immune functions, inflammation, and QoL in cancer patients were also addressed. Adverse events associated with mycotherapy were also investigated. Emerging data point to a potential role of G. lucidum for modulating the carcinogenic potential of GI microbiota, which suggests a new complementary and integrated approach to breast cancer treatment.

U2 - 10.18632/oncotarget.24984

DO - 10.18632/oncotarget.24984

M3 - Review article

C2 - 29872510

VL - 9

SP - 24837

EP - 24856

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -